![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SRC |
Gene summary for SRC |
![]() |
Gene information | Species | Human | Gene symbol | SRC | Gene ID | 6714 |
Gene name | SRC proto-oncogene, non-receptor tyrosine kinase | |
Gene Alias | ASV | |
Cytomap | 20q11.23 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | P12931 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
6714 | SRC | LZE4T | Human | Esophagus | ESCC | 4.17e-04 | 8.87e-02 | 0.0811 |
6714 | SRC | LZE8T | Human | Esophagus | ESCC | 6.35e-03 | 5.66e-02 | 0.067 |
6714 | SRC | LZE20T | Human | Esophagus | ESCC | 3.88e-06 | 1.87e-01 | 0.0662 |
6714 | SRC | LZE22T | Human | Esophagus | ESCC | 2.39e-03 | 1.69e-01 | 0.068 |
6714 | SRC | LZE24T | Human | Esophagus | ESCC | 4.07e-12 | 3.74e-01 | 0.0596 |
6714 | SRC | P1T-E | Human | Esophagus | ESCC | 1.99e-04 | 2.78e-01 | 0.0875 |
6714 | SRC | P2T-E | Human | Esophagus | ESCC | 3.86e-10 | 1.07e-01 | 0.1177 |
6714 | SRC | P4T-E | Human | Esophagus | ESCC | 2.75e-19 | 1.82e-01 | 0.1323 |
6714 | SRC | P8T-E | Human | Esophagus | ESCC | 3.27e-12 | 2.30e-01 | 0.0889 |
6714 | SRC | P9T-E | Human | Esophagus | ESCC | 1.69e-09 | 7.57e-02 | 0.1131 |
6714 | SRC | P10T-E | Human | Esophagus | ESCC | 4.36e-10 | 1.94e-01 | 0.116 |
6714 | SRC | P11T-E | Human | Esophagus | ESCC | 4.18e-12 | 3.10e-01 | 0.1426 |
6714 | SRC | P12T-E | Human | Esophagus | ESCC | 2.98e-17 | 3.51e-01 | 0.1122 |
6714 | SRC | P15T-E | Human | Esophagus | ESCC | 6.55e-13 | 2.98e-01 | 0.1149 |
6714 | SRC | P16T-E | Human | Esophagus | ESCC | 8.91e-15 | 2.73e-01 | 0.1153 |
6714 | SRC | P17T-E | Human | Esophagus | ESCC | 6.33e-06 | 2.31e-01 | 0.1278 |
6714 | SRC | P20T-E | Human | Esophagus | ESCC | 5.91e-17 | 3.27e-01 | 0.1124 |
6714 | SRC | P21T-E | Human | Esophagus | ESCC | 3.51e-20 | 4.69e-01 | 0.1617 |
6714 | SRC | P22T-E | Human | Esophagus | ESCC | 6.37e-11 | 2.23e-01 | 0.1236 |
6714 | SRC | P23T-E | Human | Esophagus | ESCC | 2.79e-14 | 2.57e-01 | 0.108 |
Page: 1 2 3 4 5 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00069139 | Cervix | CC | nucleocytoplasmic transport | 71/2311 | 301/18723 | 4.04e-08 | 2.54e-06 | 71 |
GO:00511699 | Cervix | CC | nuclear transport | 71/2311 | 301/18723 | 4.04e-08 | 2.54e-06 | 71 |
GO:000838010 | Cervix | CC | RNA splicing | 76/2311 | 434/18723 | 9.79e-04 | 8.19e-03 | 76 |
GO:000037710 | Cervix | CC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 55/2311 | 320/18723 | 6.71e-03 | 3.70e-02 | 55 |
GO:000039810 | Cervix | CC | mRNA splicing, via spliceosome | 55/2311 | 320/18723 | 6.71e-03 | 3.70e-02 | 55 |
GO:000037510 | Cervix | CC | RNA splicing, via transesterification reactions | 55/2311 | 324/18723 | 8.61e-03 | 4.44e-02 | 55 |
GO:0008380 | Colorectum | AD | RNA splicing | 169/3918 | 434/18723 | 3.59e-18 | 2.04e-15 | 169 |
GO:0000377 | Colorectum | AD | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 130/3918 | 320/18723 | 5.88e-16 | 2.16e-13 | 130 |
GO:0000398 | Colorectum | AD | mRNA splicing, via spliceosome | 130/3918 | 320/18723 | 5.88e-16 | 2.16e-13 | 130 |
GO:0000375 | Colorectum | AD | RNA splicing, via transesterification reactions | 131/3918 | 324/18723 | 7.11e-16 | 2.22e-13 | 131 |
GO:0006913 | Colorectum | AD | nucleocytoplasmic transport | 102/3918 | 301/18723 | 1.00e-07 | 4.85e-06 | 102 |
GO:0051169 | Colorectum | AD | nuclear transport | 102/3918 | 301/18723 | 1.00e-07 | 4.85e-06 | 102 |
GO:0000380 | Colorectum | AD | alternative mRNA splicing, via spliceosome | 33/3918 | 77/18723 | 1.13e-05 | 2.55e-04 | 33 |
GO:00083801 | Colorectum | SER | RNA splicing | 123/2897 | 434/18723 | 3.84e-12 | 8.41e-10 | 123 |
GO:00003751 | Colorectum | SER | RNA splicing, via transesterification reactions | 90/2897 | 324/18723 | 8.68e-09 | 7.50e-07 | 90 |
GO:00003771 | Colorectum | SER | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 89/2897 | 320/18723 | 9.82e-09 | 8.14e-07 | 89 |
GO:00003981 | Colorectum | SER | mRNA splicing, via spliceosome | 89/2897 | 320/18723 | 9.82e-09 | 8.14e-07 | 89 |
GO:00069131 | Colorectum | SER | nucleocytoplasmic transport | 77/2897 | 301/18723 | 3.39e-06 | 1.32e-04 | 77 |
GO:00511691 | Colorectum | SER | nuclear transport | 77/2897 | 301/18723 | 3.39e-06 | 1.32e-04 | 77 |
GO:00003801 | Colorectum | SER | alternative mRNA splicing, via spliceosome | 24/2897 | 77/18723 | 4.08e-04 | 6.09e-03 | 24 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa04144210 | Esophagus | ESCC | Endocytosis | 186/4205 | 251/8465 | 9.74e-16 | 4.66e-14 | 2.39e-14 | 186 |
hsa05208211 | Esophagus | ESCC | Chemical carcinogenesis - reactive oxygen species | 168/4205 | 223/8465 | 1.83e-15 | 6.81e-14 | 3.49e-14 | 168 |
hsa05418211 | Esophagus | ESCC | Fluid shear stress and atherosclerosis | 109/4205 | 139/8465 | 2.00e-12 | 3.72e-11 | 1.90e-11 | 109 |
hsa05131211 | Esophagus | ESCC | Shigellosis | 176/4205 | 247/8465 | 2.27e-12 | 4.01e-11 | 2.05e-11 | 176 |
hsa05130211 | Esophagus | ESCC | Pathogenic Escherichia coli infection | 142/4205 | 197/8465 | 8.21e-11 | 1.06e-09 | 5.42e-10 | 142 |
hsa05167211 | Esophagus | ESCC | Kaposi sarcoma-associated herpesvirus infection | 136/4205 | 194/8465 | 4.28e-09 | 4.22e-08 | 2.16e-08 | 136 |
hsa0513526 | Esophagus | ESCC | Yersinia infection | 100/4205 | 137/8465 | 1.80e-08 | 1.59e-07 | 8.12e-08 | 100 |
hsa0520529 | Esophagus | ESCC | Proteoglycans in cancer | 138/4205 | 205/8465 | 1.79e-07 | 1.40e-06 | 7.15e-07 | 138 |
hsa0520325 | Esophagus | ESCC | Viral carcinogenesis | 137/4205 | 204/8465 | 2.47e-07 | 1.88e-06 | 9.62e-07 | 137 |
hsa05417211 | Esophagus | ESCC | Lipid and atherosclerosis | 143/4205 | 215/8465 | 3.30e-07 | 2.45e-06 | 1.26e-06 | 143 |
hsa05163210 | Esophagus | ESCC | Human cytomegalovirus infection | 148/4205 | 225/8465 | 5.73e-07 | 4.00e-06 | 2.05e-06 | 148 |
hsa05100211 | Esophagus | ESCC | Bacterial invasion of epithelial cells | 59/4205 | 77/8465 | 1.05e-06 | 6.76e-06 | 3.46e-06 | 59 |
hsa0452030 | Esophagus | ESCC | Adherens junction | 69/4205 | 93/8465 | 1.08e-06 | 6.83e-06 | 3.50e-06 | 69 |
hsa0521910 | Esophagus | ESCC | Bladder cancer | 35/4205 | 41/8465 | 1.91e-06 | 1.15e-05 | 5.87e-06 | 35 |
hsa051619 | Esophagus | ESCC | Hepatitis B | 108/4205 | 162/8465 | 7.68e-06 | 4.15e-05 | 2.12e-05 | 108 |
hsa04137210 | Esophagus | ESCC | Mitophagy - animal | 54/4205 | 72/8465 | 9.33e-06 | 4.96e-05 | 2.54e-05 | 54 |
hsa046259 | Esophagus | ESCC | C-type lectin receptor signaling pathway | 73/4205 | 104/8465 | 1.57e-05 | 7.98e-05 | 4.09e-05 | 73 |
hsa0512018 | Esophagus | ESCC | Epithelial cell signaling in Helicobacter pylori infection | 52/4205 | 70/8465 | 2.17e-05 | 1.07e-04 | 5.47e-05 | 52 |
hsa0451020 | Esophagus | ESCC | Focal adhesion | 127/4205 | 203/8465 | 1.25e-04 | 4.99e-04 | 2.56e-04 | 127 |
hsa0152110 | Esophagus | ESCC | EGFR tyrosine kinase inhibitor resistance | 55/4205 | 79/8465 | 2.44e-04 | 8.78e-04 | 4.50e-04 | 55 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SRC | SNV | Missense_Mutation | novel | c.257N>C | p.Val86Ala | p.V86A | P12931 | protein_coding | tolerated(0.12) | probably_damaging(0.97) | TCGA-86-A4D0-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | etoposide | CR |
SRC | SNV | Missense_Mutation | rs370773419 | c.736N>T | p.Thr246Ser | p.T246S | P12931 | protein_coding | tolerated(0.69) | benign(0) | TCGA-95-7039-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
SRC | SNV | Missense_Mutation | novel | c.871N>T | p.Gly291Cys | p.G291C | P12931 | protein_coding | deleterious(0.01) | probably_damaging(0.965) | TCGA-18-3410-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
SRC | SNV | Missense_Mutation | novel | c.611N>T | p.His204Leu | p.H204L | P12931 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-33-AAS8-01 | Lung | lung squamous cell carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SRC | SNV | Missense_Mutation | novel | c.97C>T | p.Pro33Ser | p.P33S | P12931 | protein_coding | tolerated(0.12) | benign(0) | TCGA-90-A4ED-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
SRC | deletion | Frame_Shift_Del | novel | c.484_490delNNNNNNN | p.Glu162TyrfsTer39 | p.E162Yfs*39 | P12931 | protein_coding | TCGA-58-A46N-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | PD | ||
SRC | SNV | Missense_Mutation | c.1360N>G | p.Leu454Val | p.L454V | P12931 | protein_coding | deleterious(0.02) | probably_damaging(0.981) | TCGA-BR-8588-01 | Stomach | stomach adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
SRC | SNV | Missense_Mutation | novel | c.1538A>G | p.Glu513Gly | p.E513G | P12931 | protein_coding | deleterious(0) | benign(0.426) | TCGA-KB-A6F7-01 | Stomach | stomach adenocarcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | CR |
SRC | deletion | Frame_Shift_Del | c.397delN | p.Gly133AlafsTer70 | p.G133Afs*70 | P12931 | protein_coding | TCGA-CG-5723-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |||
SRC | SNV | Missense_Mutation | c.1521G>C | p.Glu507Asp | p.E507D | P12931 | protein_coding | tolerated(0.22) | probably_damaging(0.949) | TCGA-BJ-A3EZ-01 | Thyroid | thyroid carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
6714 | SRC | CLINICALLY ACTIONABLE, KINASE, TYROSINE KINASE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR, ENZYME | CEDIRANIB | CEDIRANIB | ||
6714 | SRC | CLINICALLY ACTIONABLE, KINASE, TYROSINE KINASE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR, ENZYME | inhibitor | CHEMBL24828 | VANDETANIB | |
6714 | SRC | CLINICALLY ACTIONABLE, KINASE, TYROSINE KINASE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR, ENZYME | inhibitor | CHEMBL3545196 | PD-0166285 | |
6714 | SRC | CLINICALLY ACTIONABLE, KINASE, TYROSINE KINASE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR, ENZYME | DOVITINIB | DOVITINIB | ||
6714 | SRC | CLINICALLY ACTIONABLE, KINASE, TYROSINE KINASE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR, ENZYME | TYRPHOSTIN A9 | 11112699 | ||
6714 | SRC | CLINICALLY ACTIONABLE, KINASE, TYROSINE KINASE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR, ENZYME | KX2-361 | KX2-361 | ||
6714 | SRC | CLINICALLY ACTIONABLE, KINASE, TYROSINE KINASE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR, ENZYME | AZD0530 | SARACATINIB | ||
6714 | SRC | CLINICALLY ACTIONABLE, KINASE, TYROSINE KINASE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR, ENZYME | inhibitor | 178102599 | ||
6714 | SRC | CLINICALLY ACTIONABLE, KINASE, TYROSINE KINASE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR, ENZYME | inhibitor | CHEMBL1421 | DASATINIB | |
6714 | SRC | CLINICALLY ACTIONABLE, KINASE, TYROSINE KINASE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR, ENZYME | inhibitor | 354702286 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |